Question 1

Where is the Bayer AG NA stock traded?

Accepted Answer

The Bayer AG NA stock trades under the ticker BAYN.XETRA on the XETRA exchange. ISIN: DE000BAY0017.

Question 2

What does Bayer AG NA do?

Accepted Answer

Bayer AG NA is a company characterized by the following investment thesis:

Question 3

What are the key metrics for BAYN.XETRA?

Accepted Answer

Key metrics for BAYN.XETRA include valuation (P/E 0, P/S 1, P/B 1.6), profitability (profit margin -3.83%, ROE -5.69%), and growth (revenue —, earnings —). Market capitalization is 46.95B EUR. These metrics give an overview of the company's financial performance and valuation.

Question 4

How has Bayer AG NA's stock price performed?

Accepted Answer

Bayer AG NA's stock has returned — over 1 year, — over 3 years, and — over 5 years. Performance can vary depending on market conditions and company developments.

Question 5

How is BAYN.XETRA valued?

Accepted Answer

BAYN.XETRA has the following valuation metrics: P/E Ratio: 0, P/S Ratio: 1, P/B Ratio: 1.6. These metrics help assess whether the stock is fairly valued compared to its fundamentals.

Question 6

Does BAYN.XETRA pay dividends?

Accepted Answer

Yes, BAYN.XETRA pays dividends with a dividend yield of 0.2%. Dividends can be an important component of the total return on an investment.

Question 7

What are the key risks when investing in BAYN.XETRA?

Accepted Answer

Key risks for BAYN.XETRA include: Bayer AG operates across three markets: pharmaceuticals (specialty medicines and oncology), crop science (seeds, traits and crop-protection), and consumer health. Its most relevant competitors are major global pharma groups—Pfizer, Novartis, Roche, AstraZeneca, Merck—and large agricultural players including Corteva, Syngenta, BASF, and FMC. In consumer health, it competes with Haleon, Kenvue, Reckitt, and Perrigo. The company faces material litigation and regulatory risk tied to Roundup and glyphosate, alongside pipeline pressures and patent expirations. Its Crop Science division remains exposed to commodity and crop-demand cycles.Ongoing litigation and settlements related to glyphosate expose Bayer to material cash outflows, potential operational constraints, and reputational risk, based on active cases and recent settlement activity the company has disclosed.Pharmaceutical pipeline and patent expiry risk: if exclusivity lapses or new drug launches underperform expectations, margins and growth could lag behind larger specialty competitors.Crop science companies face exposure to commodity price fluctuations, weather patterns, and regulatory shifts—particularly around pesticide approvals and seed trait regulations—that can quickly reshape both demand and product availability.Integration, portfolio, and capital-allocation risk—including restructuring or asset separations designed to isolate liabilities, such as recent moves to separate U.S. glyphosate assets—and their potential impact on cash flow and credit metrics.Investors should consider these risk factors carefully before making an investment decision.

Question 8

Who are the main competitors of Bayer AG NA?

Accepted Answer

Bayer AG NA competes with several listed peers in its sector. Bayer AG operates across pharmaceuticals, crop science (seeds and pesticides), and consumer health. Its competitors include large integrated pharmaceutical companies in prescription drugs and diagnostics, alongside specialist crop-science and agrochemical firms. The company carries material legacy litigation and cash-flow risks tied to glyphosate (Roundup) and other legal exposures. Beyond these, it faces typical pharmaceutical risks—R&D pipeline execution, patent cliffs, pricing and regulatory pressure—and crop-science risks including commodity cycles, seed and trait development, intellectual property, and regulatory approvals.Pfizer Inc. (PFE.NYSE)Novartis AG (NOVN.SIX)Roche Holding AG (ROG.SIX)Merck & Co., Inc. (MRK.NYSE)AstraZeneca plc (AZN.LSE)Corteva, Inc. (CTVA.NYSE)FMC Corporation (FMC.NYSE)Haleon plc (consumer health competitor, spun out from GSK) (HLN.LSE)Kenvue Inc. (consumer health competitor, spun out from J&J) (KVUE.NYSE)These competitors influence pricing power, growth opportunities and relative valuation.

Question 9

When does Bayer AG NA report earnings?

Accepted Answer

Bayer AG NA's next earnings report date is November 3, 2026.

Period	P/E Ratio	P/S Ratio	P/B Ratio	P/CF Ratio
Current	-27.0	1.0	1.6	11.3
1Y ago	-7.7	0.6	0.9	3.7
3Y ago	35.8	1.1	1.4	19.5
5Y ago	-17.5	1.1	1.5	24.1

Bayer AG NA P/E & Valuation

Valuation Metrics

Historical valuation trends

Get More Stock Analyses Like This

Unlock Premium

Full Analysis

Ready for professional stock analysis?

Try for Free

Learn more